参考文献/References:
[1] Watanabe Y,Tahara K,Hirai A,et al.Subtypes of ani-TSH receptor antibodies classified by various as-says using CHO cells expressing wild-type or chimeric human TSH receptor[J].Thyroid,1997,7(1):13-19.
[2] Akamizu T,M oriyama K,Miura M,et al.Characteri-zation of combinant monoclonal antithyrotropin recep-tor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves’ disease:epitope and binding study of two stimulatory TSHRAbs[J].Endocrinolo-gy,1999,140(4):1594-1601.
[3] AkamizuT,Kohn LD,Hiratani H,et al.Hashimoto’s thyroiditis with heterogeneous antithy-rotropin receptor antibodies:unique epitopes may con-tribute to the regulation of thyroid function by the an-tibodies[J].J Clin Endocrinol Metab,2000,85(6):2116-2121.
[4] Meller J,Jauho A,Hufner M,et al.Disseminated thyroid autonomy or Graves’ disease:revaluation by a second generation TSH receptor antibody assay[J].Thyroid,2000,10(12):1073-1079.
[5] Costagliola S,Morgenthaler NG,Hoermann R,et al.Second generation assay for thyrotropin receptor anti-bodies has superior diagnostic sensitivity for Graves’ disease[J].J Clin Endocrinol Metab,1999,84(1):90-97.
[6] Khoo DH,Eng PH,Ho SC,et al.Graves’ ophthal-mopathy in the absence of elevated free thyroxine andtriiodothyronine levels:prevalence,natural history,and thyrotropin receptor antibody levels[J].Thyroid,2000,20(22):1093-1100.
[7] Morgenthaler NG,Pampel I,Aust G.Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor[J].Horm Metab Res,1998,30(3):162-168.
[8] Giordabo C,Stassi G,De Mria R,et al.Potential in-volve,ent of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis[J].Scienee,1997,275:960-963.
[9] Noh JY,Hamada N,Inoue Y,et al.Thyroid-stimu-lating antibody is related to Graves’ ophthalmopathy,but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease[J].Thyroid,2000,10(9):809-813.
[10] Khoo DH,Ho SC,Seah LL,et al.The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of oph-thalmopathy[J].Thyroid,1999,9(12):1175-1180.
[11] Gerding MN,van der Meer JW,Broenink M,et al.Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy[J].Clin Endocrinol,2000,52(3):267-271.
[12] Iitaka M,Momotani N,Hisaoka T,et al.TSH recep-tor antibody-associated thyroid dysfunction following subacute thyroiditis[J].Clin Endocrinol,1998,48(4):445-453.
[13] Takasu N,Yamashiro K,Komiya I,et al.Remission of Graves’ hyperthyroidism predicted by smooth de-creases of thyroid-stimulating antibody and thy-rotropin-binding inhibitor immunoglobulin during an-tithyroid drug treatment[J].Thyroid,2000,10:891-896.
[14] Momotani N,Yamashita R,Makino F,et al.Thyroid function in wholly breast-feeding infants whose moth-ers take high doses of propylthiouracil[J].Clin En-docrinol,2000.53(2).177-181.
[15] Jones BM,Kwok CC,Kung AW,et al.Effect of ra-dioactive iodine therapy on cytokine production in Graves’ disease:transient increases in interleukin-4(IL-4),IL-6,IL-10,and tumor necrosis factor-alpha,with longn term increses in interferon-gamma produc-tion[J].J Clin Endocrinol Metab,1999,84(11):4106-4110.
[16] Nygaard B,Knudsen JH,Hegedus L,et al.Thy-rotropin receptor antibodies and Graves’ disease,a side-effect of 131 I treatment in patients with nontoxicgoiter[J].J Clin Endocrinol Metab,1997,82 (9):2926-2930.